Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder

<p>12-CK Score from RNA Sequencing</p>

Gardado en:
Detalles Bibliográficos
Autor Principal: Roger Li (17078665) (author)
Outros autores: Wade J. Sexton (17078668) (author), Jasreman Dhillon (15212961) (author), Anders Berglund (14954401) (author), Shreyas Naidu (17078671) (author), Gustavo Borjas (17078674) (author), Kyle Rose (17078677) (author), Youngchul Kim (9092151) (author), Xuefeng Wang (14955103) (author), Jose R. Conejo-Garcia (14955115) (author), Rohit K. Jain (17078680) (author), Michael A. Poch (17078683) (author), Philippe E. Spiess (17078686) (author), Julio Pow-Sang (17078689) (author), Scott M. Gilbert (17078692) (author), Jingsong Zhang (15037632) (author)
Publicado: 2025
Subjects:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase II clinical trials
Genitourinary Cancers
Bladder cancer
Immunotherapy
Checkpoint blockade
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
Sexa o primeiro en deixar un comentario!
You must be logged in first

Títulos similares